Neuromagen Pharma News
5 articles
growth-positive
Neuromagen Pharma Announces the Appointment of Professor Gal Ifergane, Head of the Neurology Department at Soroka Medical Center, to its Scientific Advisory Board
Neuromagen Pharma has established a Scientific Advisory Board and appointed Prof. Gal Ifergane as its first member. The company is developing a new class of drugs for degenerative and senescence-associated diseases. Prof. Iferganes expertise in neurology will be valuable as the company moves towards clinical trials. Neuromagens lead drug candidate is AGS-499, which activates telomerase reverse transcriptase (TERT) and shows promise in treating neurodegenerative diseases, type 1 diabetes, fertility, and cardiovascular diseases. The company aims to submit an IND and conduct a First-in-Human Clinical Study for AGS-499. Prof. Ifergane is based in Beer Sheva, Israel, and has a strong background in clinical neurology and research. Neuromagen Pharma is focused on leveraging digital and biomed technologies for medical care.
PartnersManagement Changes
growth-positive
Neuromagen Pharma Ltd. Receives FDA Orphan Drug Designation for its AGS-499 Drug Candidate to Slow the Progression of ALS (Amyotrophic Lateral Sclerosis) | BioSpace
Neuromagen Pharma has received FDA Orphan Drug Designation for its lead drug candidate, AGS-499, which has shown effectiveness in delaying the onset and progression of ALS. The designation provides seven years of marketing exclusivity for AGS-499. The drug activates telomerase reverse transcriptase (TERT) and has demonstrated efficacy in ALS, Alzheimers, diabetes, fertility, and cardiovascular disease. Neuromagen plans to begin clinical trials for AGS-499 and is pursuing collaborations with pharmaceutical partners in other therapeutic areas.
CustomersPartners
growth-positive
Neuromagen Pharma Announces the Approval of a NIS 1.8M Budget from the Israel Innovation Authority R&D Fund Incentive Program
Neuromagen Pharma has received approval from the Israel Innovation Authority for a NIS 1.3 million grant to support the development of their lead drug candidate, AGS-499. The grant will be used for IND submission and first-in-human clinical trials, expected in 2024. AGS-499 is a small molecule activator of telomerase reverse transcriptase, which has shown promising effects in delaying the onset and progression of ALS. The approval of the grant is seen as a mark of quality for Neuromagens science and team. The company will also be presenting at the BIO-Europe Spring partnering conference.
Investment
growth-positive
Neuromagen Pharma to Present at the BIO-Europe Spring 2022 Conference
Neuromagen Pharma Ltd., a company developing telomerase-targeting drugs for degenerative and senescence-associated diseases, will provide an overview at the BIO-Europe Spring partnering conference. The company is developing patent-protected small molecules that activate telomerase reverse transcriptase, an aging-related enzyme. Their lead drug candidate, AGS-499, has shown efficacy in models of ALS and other degenerative conditions. Neuromagen is seeking collaborations to advance their non-core therapeutic areas. The companys CEO expressed excitement about presenting at the conference and engaging in partnering discussions. Neuromagen Pharma is an early-stage pharmaceutical company focused on developing innovative small molecules that activate telomerase.
PartnersExpand
growth-positive
Israeli drug that slowed Alzheimer's, ALS in mice gets funding to start trials
Israeli-designed molecules that have shown effectiveness in delaying Alzheimers and amyotrophic lateral sclerosis in mice are set to begin the approval process for human use. The molecules were developed by Prof. Esther Priel and her colleagues at Ben Gurion University of the Negev, who formed the company Neuromagen Pharma. The company recently secured a multi-million-dollar investment from an unidentified Israeli funder, allowing them to move forward with clinical trials. The drug is expected to delay the onset and progression of the diseases and improve the quality of life. The specific amount of the investment was not disclosed.
Investment
